nemvaleukin alfa
Generic: nemvaleukin
nemvaleukin alfa: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Mural Oncology plc (MURA) | Phase 3 |
Clinical Trials (1)
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
Frequently asked questions
Who is developing nemvaleukin alfa?
nemvaleukin alfa is being developed by Mural Oncology plc.
How many clinical trials involve nemvaleukin alfa?
BioSniper tracks 1 clinical trial involving nemvaleukin alfa.
Get deeper analysis on nemvaleukin alfa
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis